Skip to content
Agree.net – Lifestyle
Author:
Confo Therapeutics
Confo Therapeutics Announces Encouraging Preclinical Data for Post-bariatric Hypoglycemia Candidate CFTX-2034 at ENDO 2026
June 15, 2026
Security Federal Corporation Announces Increase in First Quarter Earnings
May 3, 2026
Confo Therapeutics Announces Phase 2 Clinical Trial Initiation by Lilly for Peripheral Pain Candidate, CFTX-1554
April 30, 2026